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Abstract
Dengue virus Type 2 (DENV-2) is predominant serotype causing major dengue epidemics. There are a number of
studies carried out to find its effective antiviral, however to date, there is still no molecule either from peptide or small
molecules released as a drug. The present study aims to identify small molecules inhibitor from National Cancer
Institute database through virtual screening. One of the hits, D0713 (IC  = 62 μM) bearing thioguanine scaffold was
derivatised into 21 compounds and evaluated for DENV-2 NS2B/NS3 protease inhibitory activity. Compounds 18 and
21 demonstrated the most potent activity with IC  of 0.38 μM and 16 μM, respectively. Molecular dynamics and
MM/PBSA free energy of binding calculation were conducted to study the interaction mechanism of these compounds
with the protease. The free energy of binding of 18 calculated by MM/PBSA is -16.10 kcal/mol compared to the known
inhibitor, panduratin A (-11.27 kcal/mol), which corroborates well with the experimental observation. Results from
molecular dynamics simulations also showed that both 18 and 21 bind in the active site and stabilised by the
formation of hydrogen bonds with Asn174. © 2019 Hariono et al. This is an open access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original author and source are credited.
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